Imagyn sells minimal access line for $34 million:
This article was originally published in Clinica
Executive Summary
Imagyn Medical Technologies has completed the sale of its minimal access surgery product line to CONMED for $33.9 million. This is based on CONMED's closing share price of $26.10 on July 6. This compares with a transaction value of $29.7 million when the deal was announced.